Introduction {#Sec1}
============

The first description of the syndrome was probably as a cluster headache variant with strictly unilateral, continuous headache responding to indometacin \[[@CR1]\]. Subsequently, the disorder was named hemicrania continua (HC) \[[@CR2]\]: the index patients were a woman (age 63 years) and a man (age 53 years) who developed a strictly unilateral continuous pain from onset and were completely responsive to indometacin. Interestingly, 1 year earlier, a 49-year-old man who had a history of more than 20 years of unilateral pain, mainly localized on the left side, and also had a dramatic response to indometacin was described \[[@CR3]\].

Case Series {#Sec2}
===========

Following the description by Sjaastad and Spierings \[[@CR2]\], more than 100 cases of HC have been described. The first case series was reported in 1991 with 18 cases reviewed from the literature \[[@CR4]\]. Newman and colleagues \[[@CR5]\] described 10 new cases and reviewed 24 cases from the literature in an attempt to better describe the clinical picture and temporal profile. In 1999, Espada and colleagues \[[@CR6]\] described the long-term outcome of the indometacin response in five men and four women. Peres and colleagues \[[@CR7]\] described 34 new cases to highlight this syndrome, and Pareja and colleagues \[[@CR8]\] reviewed 16 patients with HC to assess doses and the side effects of prolonged indometacin treatment. Bigal and colleagues \[[@CR9]\] retrospectively described 10 cases, and Wheeler \[[@CR10]\] described six cases of HC in African-Americans. Klein and colleagues \[[@CR11]\] retrospectively described eight patients with HC that had neuro-ophthalmologic presentations. In 2009, Marmura and colleagues \[[@CR12]•\] retrospectively reviewed the clinical charts of 43 patients with positive response to indometacin versus 122 patients with a negative response to indometacin to identify possible clinical differences, which is in practice a very substantial issue. The authors compared the two groups for age, sex, presence or absence of specific autonomic symptoms, medication overuse, rapid onset of headache, and if the headaches met International Headache Society (IHS) criteria for migraine when severe. The study did not show any difference in the demographics or clinical characteristics of these two groups, supporting the clinical impression that it is challenging to identify clinical characteristics that can predict a response to indometacin. In the study, the frequent diagnosis of patients who did not respond to indometacin included chronic migraine with and without medication overuse, new daily--persistent headache (NDPH), nummular headache, or cervicogenic headache \[[@CR13]\]. Further, 24 of 42 patients (57%) had cranial autonomic features required by the International Classification of Headache Disorders (ICHD) \[[@CR14]\] and 55% of the patients exhibited medication overuse. In a previous study \[[@CR7]\], 25 of 34 patients (73.5%) had at least one cranial autonomic feature according to the Goadsby and Lipton criteria \[[@CR15]\], and in the most recent study \[[@CR16]••\], 37 of 39 patients (95%) with HC had at least one cranial autonomic feature. However, some of the features in the cohort are not in the current diagnostic criteria, including forehead/facial flushing, itching of the eye, eyelid edema, and a sense of aural fullness or swelling. In addition, 3 of 39 patients had side-shifting pain, and there are reports of patients with side-shifting pain in the literature \[[@CR16]••\]. Overall, it emerged that some of the current criteria for HC \[[@CR14]\] are restrictive and that there is a need for the revision of the current criteria.

Epidemiology and Sex Distribution {#Sec3}
=================================

The incidence and prevalence of HC is unknown. Initially, it was considered to be a very rare syndrome. However, the increasing number of patients identified in headache subspecialty clinics has led some to suggest the condition may be underdiagnosed \[[@CR7], [@CR17]\]. On the other hand, the diagnosis of a relatively small group of patients with HC over a period of 13 years \[[@CR16]••\] in a tertiary center, using strict indometacin-response criteria, suggests the condition is rare. Only a large population-based study will properly provide clear information about the prevalence of this condition. In the latest study of 39 patients with HC \[[@CR16]••\], the range of headache onset was between 10 and 67 years, and this data confirms the existing literature that states this condition can begin at any age; the mean age at onset is in the 30 s. In the Vaga study \[[@CR18]\], one patient had a clinical picture that resembled HC, but the indometacin trial was not attempted to confirm the diagnosis. This data suggests that the prevalence of HC is possibly no more than 1 in 1838: in effect, a rare condition.

A preponderance of women (5:1) initially was noted in the first 18 cases reported by Bordini and colleagues \[[@CR4]\]. However, the female preponderance has decreased with more reported cases to 1.8:1 \[[@CR5]\]. In a study of 34 patients, the female-to-male ratio was 2.4:1 \[[@CR7]\], and in the recent study of 39 patients \[[@CR16]••\], there was a small female preponderance (1.6:1), which is in line with the literature and is less than is seen in patients with migraine.

Family History and Genetics {#Sec4}
===========================

A family history of clear HC has not been reported in the available literature. Pareja and colleagues \[[@CR19]\] described a patient with episodic HC who had a sister with HC, but unfortunately, detailed information regarding the headache was not reported. In 1999, a case report describing a coincidental occurrence of familial hemiplegic migraine and primary HC was suggested to be unlikely to be due to chance because of a very low incidence of both headache types, suggesting a common pathophysiological link \[[@CR20]\]. Specific genetic studies have not been carried out in HC, and the rarity of this disorder will make this difficult. In the study of 39 patients with HC \[[@CR16]••\], the relationship between the presence of migrainous biology was assessed and it was found that migraine or headache not otherwise specified was present in the family history of 61% of patients. However, this data does not exclude the possibility that some of the relatives could have HC because the trial was not assessed due to the design of the study. Therefore, future studies should focus on performing an indometacin trial on the relatives of patients with HC who have a clinical picture suggestive of HC.

Pathophysiology {#Sec5}
===============

The pathophysiology of HC is poorly understood. Craniovascular involvement has been investigated with orbital phlebography in six patients, but only in one patient was there an abnormality consisting of bilateral narrowing of the ophthalmic veins, which may have been a nonspecific finding with unilateral pain \[[@CR21]\]. The pain pressure thresholds are reported to be reduced in patients with HC \[[@CR22]\], similar to cases of paroxysmal hemicrania and cluster headache (CH) \[[@CR23]\]. Pupillometric studies have shown no clear abnormality in HC \[[@CR24]\], and studies of facial sweating have shown modest changes similar to those seen in PH \[[@CR25]\].

An important development resulting in greater insight into the pathophysiology of primary headache syndrome comes from functional brain imaging that suggested a role for subcortical neural structures \[[@CR26]\]. A positron emission tomography study in HC showed activation of the contralateral posterior hypothalamus, with correlates with hypothalamic activation in CH and the trigeminal autonomic cephalalgias (TACs), and also in the dorsal rostral pons, ventrolateral midbrain (extending over the red nucleus and substantia nigra), and pontomedullary junction \[[@CR27]\]. The ipsilateral dorsal pontine region is similar to that seen in migraine \[[@CR28]--[@CR30]\]. These findings, together with the clinical phenotype, suggest HC is unique and overlaps with both TACs and migraine. The complete response to indometacin may be due in part to the activation of the ventral midbrain, red nucleus, and substantia nigra, which is active during the painful exacerbation of HC and inactive after indometacin administration. It is interesting that TACs and HC show activation of posterior hypothalamus and prominent cranial autonomic features are present in association with headache.

It has been suggested the cranial autonomic features may be prominent in these syndromes owing to central disinhibition of the trigeminal-autonomic reflex by the hypothalamus \[[@CR31]\]. Indeed, there are direct hypothalamic--trigeminal connections \[[@CR32]\], and the hypothalamus is known to have a modulatory role on the nociceptive pathways \[[@CR33]\]. The activation of the region of the posterior hypothalamus observed in the TACs and HC with neuroimaging studies underlines an important role in the primary headache syndromes for this region. Only further studies and detailed anatomical work will allow us to understand the role of the region more completely in HC and indeed, more broadly in the TACs.

Clinical Features and Diagnosis {#Sec6}
===============================

The current second edition of the ICHD \[[@CR14]\] defines HC by the presence of unilateral continuous daily headache without side shift. The pain is considered to be moderate in intensity, but there may be exacerbations of severe pain. During exacerbations, there should be at least one ipsilateral cranial autonomic symptom, such as conjunctival injection, lacrimation, nasal blockage, rhinorrhea, ptosis, or miosis. Cases of patients with side shift of pain have been noted \[[@CR16]••\], suggesting the condition is not side locked, and therefore, side shift of pain should not preclude an indometacin trial. The cranial autonomic features do not always occur with the exacerbation of the pain \[[@CR7], [@CR12]•, [@CR16]••\] and also, during a detailed interview, a wider range of cranial autonomic features can be detected \[[@CR16]••\]. The current IHS classification \[[@CR14]\] describes the pain as moderate in intensity with exacerbation of severe pain. From a recent cohort \[[@CR16]••\], it emerged that severe pain is reported in 70% of the patients, reinforcing the importance of timely diagnosis.

In addition, it also has been suggested that unilateral photophobia or phonophobia, or both, are more frequent in HC and TACs such as CH, paroxysmal hemicrania, and SUNCT (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing) than in migraine and NDPH \[[@CR34]\]. In a cohort of 39 patients \[[@CR16]••\], 79% had phonophobia, which was unilateral in 48%, and 74% had photophobia, which was unilateral in 48%. The presence of these unilateral symptoms may be clinically useful pointers; however, further comparison studies between HC and unilateral chronic migraine are needed to confirm the clinical importance of these data.

It also has emerged that more than half of the patients show signs of agitation or restlessness or both, but also, more than half of the patients have sensitivity to movement. This is useful information because it once again suggests that this condition shares some part of the TAC and migraine phenotypes, which is consistent with the functional imaging data. In the future, studies that correlate imaging and phenotype may further elucidate the basis of the symptoms our patients report.

Current criteria \[[@CR14]\] for the diagnosis of HC mandate daily and continuous pain without pain-free periods for more than 3 months. Typically, HC is a chronic condition with the episodic form occurring less often. The current classification \[[@CR14]\] does not include criteria that indicate how to classify the chronic and episodic forms based on duration and frequency of the pain. Recent data \[[@CR16]••\] confirm that chronic HC can arise de novo (primary chronic HC), or evolve from the episodic subtype (secondary HC). In addition, episodic HC can arise de novo (primary episodic form), or some patients can switch from chronic to episodic form (secondary episodic). Most of the patients described in this cohort had the primary chronic form, which is in line with the current literature \[[@CR7]\]. At present, there is not a clear classification for these two subforms, and the authors suggested the following possible classification: the term chronic should apply to patients without pain-free periods for at least 1 year, and the term episodic should apply to patients who have pain-free periods of at least 1 day.

Differential Diagnosis of Hemicrania Continua {#Sec7}
=============================================

The differential diagnosis of long-lasting unilateral headache includes HC, unilateral chronic migraine, NDPH (probably largely its migrainous subtype) \[[@CR35]\], and the other TACs when they occur with background pain, notably paroxysmal hemicrania. HC can be differentiated from chronic migraine and NDPH by the positive response to indometacin \[[@CR35]\]. The differential diagnosis between HC and paroxysmal hemicrania with interictal pain can be difficult, and certainly, a headache diary is very useful during the workup of HC. In our experience, HC typically has less prominent cranial autonomic features than paroxysmal hemicrania. Furthermore, the background pain in HC is typically more severe than the interictal pain in paroxysmal hemicrania. In addition, painful exacerbations in HC are long lasting, usually several hours, and less frequent, whereas those in paroxysmal hemicrania are short lasting, typically a few minutes to 1 h, and occur many times a day. In general, a careful history supplemented with a headache diary allows these two headache types to be dissected one from another (Table [1](#Tab1){ref-type="table"}). Table 1Comparison based on the cohorts of patients with trigeminal autonomic cephalalgia and hemicrania continuaHeadache characteristicsCluster headache\[[@CR44]\]Paroxysmal hemicrania \[[@CR45]\]SUNCT/SUNA \[[@CR46]\]Hemicrania continua \[[@CR16]\]Sex, M:F3:11:11.5:11:1.6Pain • QualitySharp/stabbing/throbbingSharp/stabbing/throbbingSharp/stabbing/throbbingThrobbing/sharp/constant • SeverityVery severeVery severeSevereModerate/severe/very severe • Distribution^a^V1 \>C2 \> V2 \> V3V1 \> C2 \> V2 \> V3V1 \> C2 \> V2 \> V3V1 \> C2 \> V2 \> V3Attacks• Frequency (per day)1--811100No pattern• Length, min30--1802--501--530 min--7 days Background painTriggers • Alcohol+ + ++--+ • Nitroglycerin+ + ++--+ + • Cutaneous----+ + +--Agitation/restlessness90%80%65%69%Episodic vs chronic, E:C90:1035:6510:9018:82Circadian/circannual periodicityPresentAbsentAbsentAbsentTreatment effects • Oxygen70%No effectNo effectNo effect • Sumatriptan, 6 mg90%20%\< 10%No effect • indometacinNo effect100%No effect100%Migraine features with attacks • Nausea50%40%25%53% • Photophobia/phonophobia65%65%25%80%^a^*C* cervical, *V* trigeminal*SUNA* short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms, *SUNCT* short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing

Diagnosis and Investigations {#Sec8}
============================

The diagnosis is made on the basis of clinical history, neurological examination, and a therapeutic trial with indometacin. The indometacin test can be performed in two different ways: by making use of an oral trial or a placebo-controlled Indotest test \[[@CR16]\]. The mean daily dosage in one cohort was 137 mg with a range of 25--225 mg \[[@CR7]\]. In another cohort of 39 patients with HC \[[@CR16]\], all patients (81%) who could tolerate oral indometacin had an absolute response to the oral trial. The range of effective daily doses in our cohort varied between 50 mg to 500 mg per day. Some three quarters of patients reported side effects at some point, whereas only about a quarter of patients reported side effects during the placebo-controlled Indotest. The latter consists of parenteral single-blind administration of indometacin, 100 or 200 mg, or placebo. The authors suggest the placebo-controlled indometacin test may be the gold standard when applied, facilitating diagnosis and research. An important question \[[@CR12]•\] that has emerged and has not been addressed yet is whether medication overuse, in particular opioids, can influence the response to indometacin \[[@CR36]\]. Medication overuse also has been reported in patients with HC \[[@CR16]••, [@CR37]\] and in our practice, we prefer to stop medication overuse, where it is possible, based on the knowledge that medication can alter the clinical picture \[[@CR38]\]. Nevertheless, we performed indometacin trials in both contexts with positive and negative outcome. However, in our original study \[[@CR16]••\], we did not specifically address this question. Future clinical and animal studies are needed to advance the knowledge in this specific field.

HC is a debilitating condition \[[@CR16]••\], but a recent study clearly showed that it still is misdiagnosed. In fact, in a cohort of 25 patients \[[@CR39]•\], not one had received the correct diagnosis before attending the headache center. Interestingly, 85% of the patients were assessed by a physician within 6 months of the onset of symptoms, but the mean latency of diagnosis was 5 years, with the average number of physicians seen before the headache was correctly diagnosed being 4.6 ± 2.2 years. A prompt diagnosis would save hospital resources and relieve the patients more quickly.

Treatment {#Sec9}
=========

There is no other drug that is consistently effective in HC. The essential management problem arises when indometacin produces peptide ulcer disease. Again, the cyclooxygenase-2 inhibitors seemed to offer a way forward, but are no longer recommended. Topiramate has been reported to be useful in HC \[[@CR40], [@CR41]\] and this is born out in practice. Similarly, greater occipital nerve injection with lidocaine and methylprednisolone has been reported to be helpful \[[@CR42]\].

In 2008, Burns and colleagues \[[@CR43]••\] prospectively described a cohort of six patients with HC that underwent occipital nerve stimulation with a bion device. They found that in a long-term follow-up, four of six patients reported a substantial improvement (80%--90%), one patient reported a 30% improvement, and one patient reported that his pain was worse by 20%. The authors suggested the new miniaturized device was safe and effective as it represents a potential new option for the treatment of HC.

Conclusions {#Sec10}
===========

Since Sjaastad and Spierings \[[@CR2]\] first coined the term in 1984, our knowledge of HC has progressed considerably in understanding both the pathophysiology and clinical presentation. It is a severe and disabling condition that deserves a prompt diagnosis. Amendments to the current criteria have been proposed based on the clinical data from a substantial cohort \[[@CR16]••\]. The gold standard treatment is indometacin, and occipital nerve stimulation may represent a valid option in a select group of patients. Future directions also will include clinical studies that try to identify possible markers that can help during the differential diagnosis between HC and unilateral chronic migraine and studies that evaluate whether medication overuse, specifically opioids, can alter the response to indometacin. We suggest that a placebo-controlled indometacin test should be considered the gold standard when applied, facilitating diagnosis and research. We also draw attention to the need for more neurologists and general practitioners to have headache training to reduce the number of patients who still are misdiagnosed.
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